Tumor Vaccines: Current Processes, Prevailing Challenges and Future Perspectives
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 1 May 2025 | Viewed by 533
Special Issue Editors
Interests: cancer therapy
Interests: research on new technologies and targets for tumor immunotherapy, as well as related immune mechanisms, with a focus on interdisciplinary integration and clinical transformation
Special Issue Information
Dear Colleagues,
In recent years, immunotherapy has gained significant momentum in the field of cancer treatment. Tumor vaccines are a favorable approach to cancer immunotherapy and include mRNA vaccines, DNA vaccines, and others. Eventually, vaccination may become the first truly personalized treatment for cancer. mRNA vaccines have become a promising platform for cancer immunotherapy as SARS-CoV-2 vaccines based on mRNA platforms have been rigorously evaluated and approved for widespread use. However, tumor vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. What is more, the adjuvant mechanisms of triggering antibody responses remain poorly understood. To conclude, there are a variety of problems to address in the area of tumor vaccines.
This Special Issue aims to discuss the latest processes, prevailing challenges, and future perspectives related to the development of tumor vaccines. In this Special Issue, original research articles, case reports, and reviews are welcome. Research areas may include (but are not limited to) the following: basic research and clinical trials on tumor vaccines, the nature of tumor vaccines, vaccine adjuvants, and delivery strategies.
We look forward to receiving your contributions.
Dr. Xingxing He
Prof. Dr. Honglin Jin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor vaccine
- mRNA vaccine
- personalized medicine
- adjuvant
- delivery strategies
- cancer immunotherapy
- personalized vaccines
